KEMRI and Tonix Pharmaceuticals Partner to Develop Mpox Vaccine in Kenya

The Kenya Medical Research Institute (KEMRI) has partnered with U.S.-based Tonix Pharmaceuticals to advance the development and clinical testing of a new mpox vaccine, TNX-801. This collaboration marks a significant step in global efforts to combat the zoonotic disease, which has seen a sharp rise in cases worldwide, particularly across Africa.   The partnership will see Tonix Pharmaceuticals, headquartered in New Jersey, work with KEMRI to conduct a Phase I clinical trial in Kenya. The study will evaluate the safety, tolerability, and immunogenicity of TNX-801, an investigat...